Entacapone: Mechanism of Action, Indications and Important Notes
Entacapone is an active substance from the group of catechol-O-methyltransferase inhibitors (COMT inhibitors) that is used exclusively in combination with levodopa and a dopa decarboxylase inhibitor (DDC inhibitor) in Parkinson's disease. Entacapone prolongs and evens out the effect of levodopa by inhibiting an important metabolic pathway of the active substance. It is available both as a single-substance preparation and in fixed combination products with levodopa and carbidopa.
Levodopa has been the most effective available substance for the treatment of Parkinson's disease for decades. However, over the course of the disease, many patients develop so-called motor fluctuations: the effect of levodopa no longer remains consistent, and phases of reduced mobility (off phases) develop between doses. Entacapone addresses exactly this problem.
Mechanism of Action
Levodopa is broken down in the body via various pathways. One of these pathways is methylation by the enzyme catechol-O-methyltransferase (COMT). Entacapone reversibly and selectively inhibits COMT in the periphery, i.e. outside the brain. This slows the breakdown of levodopa in the blood, allowing more levodopa to reach the brain where it is converted to dopamine.
Entacapone barely crosses the blood-brain barrier and therefore acts primarily peripherally. This distinguishes it from tolcapone, another COMT inhibitor that also acts centrally but must be more strictly monitored due to hepatotoxicity risks. Entacapone does not have comparable hepatotoxic potential, making it the preferred COMT inhibitor in clinical practice.
By prolonging the plasma half-life of levodopa under entacapone, fluctuations in levodopa levels are smoothed. Off phases shorten, and on phases (phases of good motor control) are prolonged. Entacapone must be taken simultaneously at each levodopa dose to achieve its full effect.
Indications
Motor Fluctuations in Parkinson's Patients
The main indication for entacapone is motor fluctuations in patients with Parkinson's disease that have arisen under levodopa therapy. Wearing-off, i.e. the end of levodopa effect before the next scheduled dose, is the most common form of such fluctuations. Entacapone is effective in this situation for reducing total daily off time.
Clinical studies demonstrate that patients on entacapone spend more time on average in good motor condition and less frequently experience phases of significant motor deterioration. Quality of life can improve noticeably as a result.
Fixed Combination with Levodopa and Carbidopa
Entacapone is also available as part of a triple combination product with levodopa and carbidopa. This fixed combination simplifies medication, as patients no longer need to take several separate tablets at each dose. It is particularly suitable for patients who respond to the combination and whose levodopa dose is stable.
Dosage Form and Dosing
Entacapone as a single preparation is available as 200 mg tablets and is taken once simultaneously at each levodopa dose. The maximum single daily dose is 200 mg per levodopa dose, with a recommended maximum daily dose that depends on the number of levodopa doses per day. Entacapone is contraindicated in patients with liver disease. Assessment and dosing are carried out by the treating neurologist.
Important Notes
When entacapone is added to existing levodopa therapy, it may initially cause an increase in dopaminergic side effects, since more levodopa reaches the brain. These include particularly involuntary movements (dyskinesias) that can occur under long-term levodopa therapy. In such cases, a reduction in the levodopa dose may be necessary, which is performed by the treating physician.
Entacapone can colour the urine reddish-orange. This is a known, harmless effect of the active substance and not a sign of disease. Patients should be informed about this particularity to avoid unnecessary concern.
Entacapone must not be abruptly discontinued. Abrupt discontinuation can lead to a significant increase in motor symptoms. Any therapy adjustment should always be made in consultation with the treating neurologist.
Adverse Effects
Possible adverse effects of entacapone include:
- Dyskinesias (involuntary movements), especially at the start of therapy
- Nausea, abdominal pain and diarrhoea, frequently at the start of treatment
- Reddish-orange discolouration of urine (harmless, caused by entacapone breakdown products)
- Dizziness and orthostatic hypotension (blood pressure drop on standing)
- Sleep disturbances
- Hallucinations in patients with a corresponding history or advanced disease
- Dry mouth
Drug Interactions
Entacapone can influence the effect of medications that are also metabolised via COMT or that act on the same enzyme systems. These include certain cardiac medications such as isoprenaline and adrenaline. Non-selective MAO inhibitors should not be used together with entacapone. Selective MAO-B inhibitors such as rasagiline can be combined in certain situations under medical supervision. A complete medication history is important before starting therapy.
Motor Complications in Parkinson's Disease
Motor fluctuations and dyskinesias are common problems in Parkinson's patients who have been treated with levodopa for several years. As the disease progresses and dopamine stores in the brain increasingly deplete, motor function becomes more sensitive to fluctuations in levodopa plasma levels. Entacapone addresses exactly this problem by ensuring more consistent levodopa levels, thereby prolonging on times and shortening off times.
In addition to pharmacological therapy, other approaches also play a role in advanced Parkinson's disease. Physiotherapy, speech therapy and occupational therapy are important components of a comprehensive treatment concept. In cases of very severe motor complications, deep brain stimulation may also be considered, which can significantly reduce motor fluctuations and dyskinesias in suitable patients. The decision about the overall treatment concept is made jointly by the patient and the neurologist.
Entacapone on Sanoliste
On Sanoliste you will find neurologists who specialise in the treatment of Parkinson's disease and related movement disorders. The care of Parkinson's patients requires regular neurological monitoring to adapt therapy to changing symptoms and detect motor complications at an early stage.
The information on this page is for general information purposes only and does not replace consultation with a physician. Entacapone is a prescription-only medicine and may only be taken following medical prescription.
Frequently Asked Questions about Entacapone
Why must entacapone always be taken together with levodopa?
Entacapone has no independent antiparkinsonian effect but exclusively prolongs the effect of levodopa. Its mechanism of action consists in inhibiting peripheral breakdown of levodopa. Without simultaneous levodopa intake, there is no target for entacapone. For this reason, taking entacapone alone without levodopa is not sensible and not approved. Entacapone must be taken simultaneously at each levodopa dose in order to optimally improve levodopa bioavailability.
Does entacapone also help with tremor?
Entacapone primarily improves motor fluctuations, i.e. the waxing and waning of levodopa effect. Tremor is a Parkinson's symptom that often responds less well to levodopa than rigidity and bradykinesia. If the levodopa effect is prolonged and stabilised by entacapone, this can also indirectly influence tremor, provided it responds to levodopa. However, this varies individually and must be assessed during therapy by the neurologist.
Can entacapone be taken on a long-term basis?
Entacapone is designed for long-term use and is used on an ongoing basis in clinical practice as long as levodopa therapy for Parkinson's continues and no contraindications arise. Regular neurological monitoring is part of long-term treatment to assess therapy response and make dose adjustments.